AtheroGenics is a publicly traded, emerging pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceutical products that address critical unmet needs in the treatment of chronic inflammatory diseases, including diabetes and atherosclerosis.
The Company’s lead compound, AGI-1067, is a first-in-class oral anti-oxidant with anti-inflammatory properties that was discovered by AtheroGenics scientists.
AtheroGenics is studying AGI-1067 in a Phase III clinical trial called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) to assess the ability of AGI-1067 to control blood sugar levels in patients with diabetes. Patient enrollment in ANDES commenced in the third quarter of 2007.
AtheroGenics was incorporated in Georgia in 1993 and is based in Alpharetta, Georgia. The Company currently has 70 employees, with a senior management team comprised of executives from leading pharmaceutical companies and academic institutions.
The company is led by Russell M. Medford, MD, PhD, President & CEO,
For more information about AtheroGenics, please visit their website.
